Philippe Convers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Philippe Convers has a total of 331 co-authors. Here are the top co-authors by number of shared publications:
- Roland Peyron
Fédération Hospitalo-Universitaire Inovpain, Nice, France; UJM, INSERM, UCBL, CNRS UMR5292, CRNL U1028, NEUROPAIN team, Saint-Etienne F-42023, France
19 shared publications - Luis Garcia-Larrea
NeuroPain Team, Centre de Recherche en Neurosciences de Lyon (CRNL), Inserm U1028, CNRS UMR5292, UJM & UCBL, Lyon, France
16 shared publications - François Mauguière
Department of Clinical Neurophysiology, Hospices Civils de Lyon, Neurological Hospital of Lyon, Lyon Neuroscience Research Center (CRNL), Brain Dynamics and Cognition Team (Dycog), INSERM U1028, CNRS UMR5292, Université Lyon 1, Lyon, France
15 shared publications D Michel
12 shared publicationsB Laurent
9 shared publications- Christelle Creac'H
Centre d’évaluation et traitement de la douleur, CHU de Saint-Étienne, laboratoire Inserm U 1028 intégration centrale de la douleur, Lyon–Saint-Étienne, France
9 shared publications
Latest Publications
- 18 May 2020
- Published by Wiley in European journal of pain
- Vol. 24 (7) , 1393-1399
A hidden mesencephalic variant of central pain
Background: Central post‐stroke pain (CPSP) can arise after lesions anywhere in the central somatosensory pathways, essentially within the spinothalamic system (STS). Although the STS can be selectively injured in the mesencephalon, CPSP has not been described in pure midbrain infarcts.Methods: Of more than 300 CPSP consecutive cases, we describe five patients who developed definite neuropathic pain following lesions circumscribed to the postero‐lateral mesencephalon.Results: The mesencephalic lesion responsible for pain was always haemorrhagic and always involved the spinothalamic tract (STT), as demonstrated by suppressed laser‐evoked potentials in every case, with or without preserved lemniscal function. In three cases the midbrain injury could be ascribed to trauma, presumably from the cerebellar tentorium. As a result of the paucity of sensory symptoms, the pain was considered as ‘psychogenic’ in two of the patients until electrophysiological testing confirmed STT involvement.Conclusion: Postero‐lateral midbrain lesions should be added to potential causes of CPSP. Because pain and spinothalamic deficits may be the only clinical sign, and because small lateral midbrain lesions may be difficult to trail with MRI, mesencephalic CPSP can be misdiagnosed as malingering or psychogenic pain for years.Significance: Selective spinothalamic injury caused by small lateral midbrain lesions is a very rare cause of central post‐stroke pain that can remain undiagnosed for years. It appears to obey to haemorrhagic, sometimes post‐traumatic lesions. Sudden development of contralateral burning pain with isolated spinothalamic deficits may be the only localizing sign, which can be easily objectively detected with electrophysiological testing.
- 18 May 2020
- Published by Wiley in European journal of pain
- Vol. 24 (7) , 1393-1399
A hidden mesencephalic variant of central pain
Background: Central post‐stroke pain (CPSP) can arise after lesions anywhere in the central somatosensory pathways, essentially within the spinothalamic system (STS). Although the STS can be selectively injured in the mesencephalon, CPSP has not been described in pure midbrain infarcts.Methods: Of more than 300 CPSP consecutive cases, we describe five patients who developed definite neuropathic pain following lesions circumscribed to the postero‐lateral mesencephalon.Results: The mesencephalic lesion responsible for pain was always haemorrhagic and always involved the spinothalamic tract (STT), as demonstrated by suppressed laser‐evoked potentials in every case, with or without preserved lemniscal function. In three cases the midbrain injury could be ascribed to trauma, presumably from the cerebellar tentorium. As a result of the paucity of sensory symptoms, the pain was considered as ‘psychogenic’ in two of the patients until electrophysiological testing confirmed STT involvement.Conclusion: Postero‐lateral midbrain lesions should be added to potential causes of CPSP. Because pain and spinothalamic deficits may be the only clinical sign, and because small lateral midbrain lesions may be difficult to trail with MRI, mesencephalic CPSP can be misdiagnosed as malingering or psychogenic pain for years.Significance: Selective spinothalamic injury caused by small lateral midbrain lesions is a very rare cause of central post‐stroke pain that can remain undiagnosed for years. It appears to obey to haemorrhagic, sometimes post‐traumatic lesions. Sudden development of contralateral burning pain with isolated spinothalamic deficits may be the only localizing sign, which can be easily objectively detected with electrophysiological testing.
- Open Access
- 1 July 2017
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 4 (4) , e371
Autoimmune episodic ataxia in patients with anti-CASPR2 antibody-associated encephalitis
Objective: To report paroxysmal episodes of cerebellar ataxia in a patient with anti–contactin-associated protein-like 2 (CASPR2) antibody-related autoimmune encephalitis and to search for similar paroxysmal ataxia in a cohort of patients with anti–CASPR2 antibody-associated autoimmune encephalitis. Methods: We report a patient with paroxysmal episodes of cerebellar ataxia observed during autoimmune encephalitis with anti-CASPR2 antibodies. In addition, clinical analysis was performed in a retrospective cohort of 37 patients with anti-CASPR2 antibodies to search for transient episodes of ataxia. Paroxysmal symptoms were further specified from the referral physicians, the patients, or their relatives. Results: A 61-year-old man with limbic encephalitis and anti-CASPR2 antibodies developed stereotyped paroxysmal episodes of cerebellar ataxia, including gait imbalance, dysarthria, and dysmetria, 1 month after the onset of the encephalitis. The ataxic episodes were specifically triggered by orthostatism and emotions. Both limbic symptoms and transient ataxic episodes resolved after treatment with steroids and IV cyclophosphamide. Among 37 other patients with anti-CASPR2 antibodies, we identified 5 additional cases with similar paroxysmal ataxic episodes that included gait imbalance (5 cases), slurred speech (3 cases), limb dysmetria (3 cases), and nystagmus (1 case). All had concomitant limbic encephalitis. Paroxysmal ataxia was not observed in patients with neuromyotonia or Morvan syndrome. Triggering factors (orthostatism or anger) were reported in 4 patients. Episodes resolved with immunomodulatory treatments in 4 patients and spontaneously in 1 case. Conclusions: Paroxysmal cerebellar ataxia must be added to the spectrum of the anti-CASPR2 antibody syndrome.
- 1 July 2017
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 4 (4) , e371
Open AccessAutoimmune episodic ataxia in patients with anti-CASPR2 antibody-associated encephalitis
Objective: To report paroxysmal episodes of cerebellar ataxia in a patient with anti–contactin-associated protein-like 2 (CASPR2) antibody-related autoimmune encephalitis and to search for similar paroxysmal ataxia in a cohort of patients with anti–CASPR2 antibody-associated autoimmune encephalitis. Methods: We report a patient with paroxysmal episodes of cerebellar ataxia observed during autoimmune encephalitis with anti-CASPR2 antibodies. In addition, clinical analysis was performed in a retrospective cohort of 37 patients with anti-CASPR2 antibodies to search for transient episodes of ataxia. Paroxysmal symptoms were further specified from the referral physicians, the patients, or their relatives. Results: A 61-year-old man with limbic encephalitis and anti-CASPR2 antibodies developed stereotyped paroxysmal episodes of cerebellar ataxia, including gait imbalance, dysarthria, and dysmetria, 1 month after the onset of the encephalitis. The ataxic episodes were specifically triggered by orthostatism and emotions. Both limbic symptoms and transient ataxic episodes resolved after treatment with steroids and IV cyclophosphamide. Among 37 other patients with anti-CASPR2 antibodies, we identified 5 additional cases with similar paroxysmal ataxic episodes that included gait imbalance (5 cases), slurred speech (3 cases), limb dysmetria (3 cases), and nystagmus (1 case). All had concomitant limbic encephalitis. Paroxysmal ataxia was not observed in patients with neuromyotonia or Morvan syndrome. Triggering factors (orthostatism or anger) were reported in 4 patients. Episodes resolved with immunomodulatory treatments in 4 patients and spontaneously in 1 case. Conclusions: Paroxysmal cerebellar ataxia must be added to the spectrum of the anti-CASPR2 antibody syndrome.
- 1 June 2017
- Published by Elsevier in Neurophysiologie Clinique
- Vol. 47 (3) , 206
MMN et P3 au propre prénom : valeurs normales chez l’adulte
- 1 June 2017
- Published by Elsevier in Neurophysiologie Clinique
- Vol. 47 (3) , 206
MMN et P3 au propre prénom : valeurs normales chez l’adulte
- 1 March 2017
- Published by Elsevier in Revue Neurologique
- Vol. 173, S196
Céphalée critique : quand l’épilepsie se manifeste par une céphalée isolée
- 1 March 2017
- Published by Elsevier in Revue Neurologique
- Vol. 173, S196
Céphalée critique : quand l’épilepsie se manifeste par une céphalée isolée
- Open Access
- 3 November 2016
- Published by Springer Nature in Trials
- Vol. 17 (1) , 1-8
Efficacy of naloxone in reducing postictal central respiratory dysfunction in patients with epilepsy: study protocol for a double-blind, randomized, placebo-controlled trial
Generalized tonic-clonic seizures (GTCSs) are the main risk factor for sudden unexpected death in epilepsy (SUDEP). Experimental and clinical data strongly suggest that the majority of SUDEP results from a postictal respiratory dysfunction progressing to terminal apnea. Postictal apnea could partly derive from a seizure-induced massive release of endogenous opioids. The main objective of this study is to evaluate the efficacy of an opioid antagonist, naloxone, administered in the immediate aftermath of a GTCS, in reducing the severity of the postictal central respiratory dysfunction. The Efficacy of Naloxone in Reducing Postictal Central Respiratory Dysfunction in Patients with Epilepsy (ENALEPSY) study is a multicenter, double-blind, randomized, placebo-controlled trial conducted in patients with drug-resistant focal epilepsy who are undergoing long-term video-electroencephalogram (EEG) monitoring (LTM) in an epilepsy monitoring unit (EMU). We plan to randomize 166 patients (1:1) to receive intravenous naloxone (0.4 mg) or placebo in the immediate aftermath of a GTCS. Because inclusion in the study needs to take place prior to the occurrence of the GTCS, and because such occurrence is observed in about one-fourth of patients undergoing LTM, we plan to include a maximum of 700 patients upon admission in the EMU. The primary endpoint will be the proportion of patients whose oxygen saturation is <90 % between 1 and 3 min after the end of a GTCS. Secondary outcomes will include the following: the proportion of patients who show postictal apnea, the occurrence and duration of postictal generalized EEG suppression, the total duration of the postictal coma, postictal pain, and the number of patients who have a second GTCS within 120 min after the intravenous injection. The demonstration of naloxone’s efficacy on the severity of postictal hypoxemia will have two primary consequences. First, naloxone would be the first and only therapeutic approach that could be delivered immediately to reverse postictal apnea. Second, demonstration that an opioid antagonist can effectively reduce postictal apnea would pave the way for an assessment of a preventive therapy for SUDEP targeting the same pathophysiological pathway using oral administration of naltrexone. ClinicalTrials.gov identifier: NCT02332447 . Registered on 5 January 2015.
- 3 November 2016
- Published by Springer Nature in Trials
- Vol. 17 (1) , 1-8
Open AccessEfficacy of naloxone in reducing postictal central respiratory dysfunction in patients with epilepsy: study protocol for a double-blind, randomized, placebo-controlled trial
Generalized tonic-clonic seizures (GTCSs) are the main risk factor for sudden unexpected death in epilepsy (SUDEP). Experimental and clinical data strongly suggest that the majority of SUDEP results from a postictal respiratory dysfunction progressing to terminal apnea. Postictal apnea could partly derive from a seizure-induced massive release of endogenous opioids. The main objective of this study is to evaluate the efficacy of an opioid antagonist, naloxone, administered in the immediate aftermath of a GTCS, in reducing the severity of the postictal central respiratory dysfunction. The Efficacy of Naloxone in Reducing Postictal Central Respiratory Dysfunction in Patients with Epilepsy (ENALEPSY) study is a multicenter, double-blind, randomized, placebo-controlled trial conducted in patients with drug-resistant focal epilepsy who are undergoing long-term video-electroencephalogram (EEG) monitoring (LTM) in an epilepsy monitoring unit (EMU). We plan to randomize 166 patients (1:1) to receive intravenous naloxone (0.4 mg) or placebo in the immediate aftermath of a GTCS. Because inclusion in the study needs to take place prior to the occurrence of the GTCS, and because such occurrence is observed in about one-fourth of patients undergoing LTM, we plan to include a maximum of 700 patients upon admission in the EMU. The primary endpoint will be the proportion of patients whose oxygen saturation is <90 % between 1 and 3 min after the end of a GTCS. Secondary outcomes will include the following: the proportion of patients who show postictal apnea, the occurrence and duration of postictal generalized EEG suppression, the total duration of the postictal coma, postictal pain, and the number of patients who have a second GTCS within 120 min after the intravenous injection. The demonstration of naloxone’s efficacy on the severity of postictal hypoxemia will have two primary consequences. First, naloxone would be the first and only therapeutic approach that could be delivered immediately to reverse postictal apnea. Second, demonstration that an opioid antagonist can effectively reduce postictal apnea would pave the way for an assessment of a preventive therapy for SUDEP targeting the same pathophysiological pathway using oral administration of naltrexone. ClinicalTrials.gov identifier: NCT02332447 . Registered on 5 January 2015.
- 1 June 2016
- Published by Elsevier in Neurophysiologie Clinique
- Vol. 46 (3) , 221-222
Exploration des réponses nociceptives du côté sain chez des patients souffrant de douleurs unilatérales : une étude en Potentiel Evoqué Laser (PELs)
- 1 June 2016
- Published by Elsevier in Neurophysiologie Clinique
- Vol. 46 (3) , 221-222
Exploration des réponses nociceptives du côté sain chez des patients souffrant de douleurs unilatérales : une étude en Potentiel Evoqué Laser (PELs)
- 1 June 2016
- Published by Elsevier in Neurophysiologie Clinique
- Vol. 46 (3) , 226
Potentiels évoqués nociceptifs par électrode concentrique : effet du CIDN
- 1 June 2016
- Published by Elsevier in Neurophysiologie Clinique
- Vol. 46 (3) , 226
Potentiels évoqués nociceptifs par électrode concentrique : effet du CIDN
- 1 June 2016
- Published by Elsevier in Neurophysiologie Clinique
- Vol. 46 (3) , 230
Crises gélastiques d’origine frontale : deux cas
- 1 June 2016
- Published by Elsevier in Neurophysiologie Clinique
- Vol. 46 (3) , 230
Crises gélastiques d’origine frontale : deux cas
- 1 April 2016
- Published by Elsevier in Neurophysiologie Clinique
- Vol. 46 (2) , 103
Potentiels évoqués pneumatiques : effets du CIDN et de l’habituation
- 1 April 2016
- Published by Elsevier in Neurophysiologie Clinique
- Vol. 46 (2) , 103
Potentiels évoqués pneumatiques : effets du CIDN et de l’habituation
- 1 April 2016
- Published by Elsevier in Neurophysiologie Clinique
- Vol. 46 (2) , 105
Épilepsie à l’alimentation : un cas
- 1 April 2016
- Published by Elsevier in Neurophysiologie Clinique
- Vol. 46 (2) , 105
Épilepsie à l’alimentation : un cas